Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 1, 2025 | $0.15 | 2025-07-21 | 2025-07-21 |
| May 1, 2025 | $0.15 | 2025-04-29 | 2025-04-29 |
| February 1, 2024 | $0.15 | 2024-01-19 | 2024-01-22 |
| November 1, 2023 | $0.15 | 2023-10-19 | 2023-10-20 |
| August 1, 2023 | $0.15 | 2023-07-20 | 2023-07-21 |
Dividends Summary
- Consistent Payer: has rewarded shareholders with 59 dividend payments over the past 19 years.
- Total Returned Value: Investors who held CYCCP shares during this period received a total of $8.85 per share in dividend income.
- Latest Payout: The most recent dividend of $0.15/share was paid 175 days ago, on August 1, 2025.
- Payment Schedule: CYCCP currently distributes dividends on a quarterly basis.
- Dividend Growth: Since 2006, the dividend payout has grown by 0.0%, from $0.15 to $0.15.
- Dividend Reliability: CYCCP has maintained or increased its dividend for 59 consecutive payments.
Company News
Cyclacel Pharmaceuticals reported preclinical study findings demonstrating that biliary tract cancer cells are sensitive to plogosertib, a PLK1 inhibitor, with potential for targeted cancer treatment using BUBR1 as a biomarker.
Cyclacel Pharmaceuticals has amended an exchange agreement with FITTERS Diversified Berhad to acquire all ordinary shares of Fitters Sdn. Bhd., issuing 19.99% of its stock and paying $1 million, with the transaction subject to stockholder approvals.
Cyclacel Pharmaceuticals published research showing its drug plogosertib could potentially treat fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer with no current approved treatments, primarily affecting adolescents and young adults.
Cyclacel Pharmaceuticals announced its Q1 2025 financial results, including a focus on the development of plogosertib and the deconsolidation of its UK subsidiary Cyclacel Limited. The company is exploring strategic alternatives to continue as a going concern, including a share exchange agreement with FITTERS Diversified Berhad.
Cyclacel Pharmaceuticals announced a change in control and leadership, with Datuk Dr. Doris Wong Sing Ee becoming the new CEO and Kiu Cu Seng appointed as Executive Director, Secretary and Chief Financial Officer.
